These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11697843)

  • 1. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.
    Quaedvlieg PF; Visser O; Lamers CB; Janssen-Heijen ML; Taal BG
    Ann Oncol; 2001 Sep; 12(9):1295-300. PubMed ID: 11697843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
    Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
    Leong WL; Pasieka JL
    J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metastasized carcinoid tumor treated with interferon and octreotide].
    Szilvás A; Székely G; Szilvási I; Jakab F
    Orv Hetil; 1998 Oct; 139(41):2455-8. PubMed ID: 9805460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
    Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of digestive system carcinoid tumors and carcinoid syndrome].
    Mondragón Sánchez RJ; Castillero Pinilla C; Saldívar Moreno C; Oñate Ocaña LF; Ruiz Molina JM; Aiello Crocifoglio V
    Rev Gastroenterol Mex; 1998; 63(4):204-10. PubMed ID: 10319670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
    Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
    Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-standing malignant pancreatic carcinoid treated with octreotide.
    Varas-Lorenzo MJ
    Rev Esp Enferm Dig; 2010 Nov; 102(11):662-6. PubMed ID: 21142389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic carcinoid tumor: changing patterns of care over two decades.
    Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
    J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
    Imtiaz KE; Monteith P; Khaleeli A
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term octreotide treatment of metastatic carcinoid tumor.
    Corleto VD; Angeletti S; Schillaci O; Marignani M; Caratozzolo M; Panzuto F; Annibale B; Delle Fave G
    Ann Oncol; 2000 Apr; 11(4):491-3. PubMed ID: 10847473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Carcinoid of the appendix. A case report].
    Spallitta SI; Termine G; Stella M; Calistro V; Marozzi P
    Minerva Chir; 2000; 55(1-2):77-87. PubMed ID: 10832290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
    Guadalupe E; Deshpande HA; Stein SM
    Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease: a case report of a patient on long-term follow-up.
    Tohyama T; Matsui K; Kitagawa K
    Intern Med; 2005 Sep; 44(9):958-62. PubMed ID: 16258211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide therapy in carcinoid disease.
    Bax ND; Woods HF; Batchelor A; Jennings M
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
    Tomassetti P; Migliori M; Corinaldesi R; Gullo L
    Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal carcinoid tumors: diagnosis and treatment.
    Stamatakos M; Kontzoglou K; Sargedi C; Tsaknaki S; Iannescu R; Safioleas C; Kaitanidi V; Safioleas M
    Chirurgia (Bucur); 2010; 105(6):759-66. PubMed ID: 21351698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the somatostatin analogue octreotide acetate in the treatment of encephalopathy associated with carcinoid tumor. Case report.
    Siu LL; Chapman W; Moore MJ
    Am J Clin Oncol; 1997 Dec; 20(6):558-61. PubMed ID: 9391539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.